Downstream Processing Industry News
-
VentiRx Pharmaceuticals Announces Exclusive, Strategic Collaboration For Development Of Novel TLR8 Agonist VTX-2337 With Celgene Corporation
10/3/2012
VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today announced the formation of an exclusive, world-wide collaboration with Celgene Corporation (NASDAQ: CELG) for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.
-
High-Dose Vitamin C Reduces Inflammation In Cancer Patients Study Shows
9/25/2012
Inflammatory responses play roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis.
-
Baxter Initiates Phase I Clinical Trial With Anti-MIF Antibody In Patients With Solid Tumors
9/5/2012
Baxter International Inc. has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company’s efforts to extend its oncology portfolio with advanced biological research and development.
-
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
8/23/2012
Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).
-
As Tuberculosis Grows More Difficult To Control, Vaccine Candidate To Prevent Disease Enters Clinical Testing
8/22/2012
Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be conducted by Johnson County Clin-Trials in Lenexa, Kansas, in close collaboration with Aeras and IDRI.
-
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
8/8/2012
Amgen (NASDAQ: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.
-
Aquavit And Green Cross Sign Strategic Collaboration MOU On IBX-001 Product Development And Commercialization In Asia
8/8/2012
Aquavit Pharmaceuticals, Inc. and Green Cross Corp. (006280:Korea SE), a leading biotechnology company inSouth Korea, signed a Memorandum of Understanding (MOU) towards establishing their strategic collaboration surrounding the development and commercialization of Aquavit's IBX-001 in Asia.
-
Sanofi Pasteur To Add 2D Barcode To Six More Vaccines
7/31/2012
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today it will transition six more products of its pediatric vaccine portfolio to two-dimensional (2D) barcoding technology by the beginning of 2013.
-
Absorption Systems Announces Novel Test Platform For Interactions With The BCRP Transporter
7/27/2012
Absorption Systems, a world leader in developing novel test systems for drug transporters, announces the availability of a long-awaited assay platform for the human BCRP transporter, also known as breast cancer resistance protein.
-
PRA Participates In Landmark Alzheimer's Prevention Clinical Trial
7/24/2012
PRA, a leading Clinical Research Organization, announces that it is participating in a groundbreaking Alzheimer's disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background.